“Alarming” spike in deaths from liver disease; Can PPIs cause lupus? IBS and depression

U.S. deaths from liver disease have risen to a “alarming rate” during the COVID-19 pandemic, revealed data from the National Vital Statistic System. (Journal of Hepatology)

Analyzes of two pharmacovigilance databases have confirmed the possible link between proton pump inhibitors (PPIs) and cases of drug-induced lupus erythematosus. (JAMA Dermatology)

Could mitochondrial targeting play a role in stop the progression of liver fibrosis? (Hepatology)

The researchers suggested that psychotherapy could potentially prevent liver disease in patients with alcohol use disorders. (Clinical gastroenterology and hepatology)

Quantitative analysis of colorectal cancer pathology slides, using QuantCRC, improved prediction of disease-free survival. (Gastroenterology)

Gut microbiome-related biomarkers may hold promise for detect colorectal cancer early. (Intestine)

In veterans, irritable bowel syndrome was associated with higher risks of depression, anxiety, post-traumatic stress disorder, and a host of other adverse effects. (Clinical gastroenterology and hepatology)

Bulevirtide was safe and effective up to 48 weeks for the treatment of patients with chronic hepatitis D with compensated cirrhosis and clinically significant portal hypertension. (Journal of Hepatology)

An estrogen exposure score, easily obtained in a clinical setting, predicted radiographic regression of hepatocellular adenomas in women who have stopped contraception. (Hepatology)

A case series has suggested that alpelisib (Piqray), a PI3K inhibitor, is a probable cause of colitis in some patients taking the drug for breast cancer. (JAMA Oncology)

  • Zaina Hamza is a writer for MedPage Today, covering gastroenterology and infectious diseases. She is based in Chicago.

Comments are closed.